Results from the completed dose-escalation of the ALLOSHRINK phase I study evaluating the allogeneic NKG2D-based CAR T-cell therapy CYAD-101 in metastatic colorectal cancer patients

Results from the completed dose-escalation of the ALLOSHRINK phase I study evaluating the allogeneic NKG2D-based CAR T-cell therapy CYAD-101 in metastatic colorectal cancer patients

Effect of chemotherapy on cellular kinetics of NKG2D-based CAR T-cells in metastatic colorectal cancer patients

Effect of chemotherapy on cellular kinetics of NKG2D-based CAR T-cells in metastatic colorectal cancer patients

Results from the completed dose-escalation phase I SHRINK study evaluating the autologous NKG2D-based CAR T-cell therapy CYAD-01 in metastatic colorectal cancer patients

Results from the completed dose-escalation phase I SHRINK study evaluating the autologous NKG2D-based CAR T-cell therapy CYAD-01 in metastatic colorectal cancer patients

Understanding the expression profile of NKG2D ligands on T cells: Implications for CAR T cell therapy

Understanding the expression profile of NKG2D ligands on T cells: Implications for CAR T cell therapy

The targeted knockdown of CD3ζ by shRNA as a platform to develop allogeneic CAR T cell therapy

The targeted knockdown of CD3ζ by shRNA as a platform to develop allogeneic CAR T cell therapy

Phase 1 studies assessing the safety and clinical activity of autologous and allogeneic NKG2D-based CAR T therapy in metastatic colorectal cancer

Phase 1 studies assessing the safety and clinical activity of autologous and allogeneic NKG2D-based CAR T therapy in metastatic colorectal cancer

Development of a next generation allogeneic CAR-T cell platform without gene editing

Development of a next generation allogeneic CAR-T cell platform without gene editing

Modeling NKG2D-based CAR-T cell therapy in animals with acute myeloid leukemia

Modeling NKG2D-based CAR-T cell therapy in animals with acute myeloid leukemia

Updated results from Phase I trials assessing a NKG2D CAR T-cell approach in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome patients

Updated results from Phase I trials assessing a NKG2D CAR T-cell approach in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome patients

Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-based CAR-T Therapy, CYAD-01, in Acute Myeloid Leukemia

Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-based CAR-T Therapy, CYAD-01, in Acute Myeloid Leukemia

Generating Allogeneic CAR T cells without Gene Editing

Generating Allogeneic CAR T cells without Gene Editing

Functional screening of different anti-B7H6 CAR designs

Functional screening of different anti-B7H6 CAR designs